amifampridine has been researched along with Myasthenia Gravis in 18 studies
Amifampridine: 4-Aminopyridine derivative that acts as a POTASSIUM CHANNEL blocker to increase release of ACETYLCHOLINE from nerve terminals. It is used in the treatment of CONGENITAL MYASTHENIC SYNDROMES.
Myasthenia Gravis: A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To give an overview of the recent data on three autoimmune neuromuscular junction disorders with the recent Food Drug Administration (FDA) approval of amifampridine [3,4-Diaminopyridine (3,4-DAP) and 3,4-diaminopyridine phosphate (3,4-DAPP) for the treatment of Lambert-Eaton myasthenic syndrome (LEMS)." | 5.12 | Neuromuscular junction disorders beyond myasthenia gravis. ( Oh, SJ, 2021) |
| " At a dosage of 18-24 mg p." | 1.27 | Improvement in neuromuscular transmission in myasthenia gravis by 3,4-diaminopyridine. ( Lundh, H; Nilsson, O; Rosén, I, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (22.22) | 18.7374 |
| 1990's | 6 (33.33) | 18.2507 |
| 2000's | 3 (16.67) | 29.6817 |
| 2010's | 3 (16.67) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, N | 1 |
| Hong, D | 1 |
| Ouyang, T | 1 |
| Meng, W | 1 |
| Huang, J | 1 |
| Li, M | 1 |
| Hong, T | 1 |
| Oh, SJ | 1 |
| Lee, MK | 1 |
| Sunwoo, IN | 1 |
| Kim, SM | 1 |
| Maselli, RA | 1 |
| Arredondo, J | 1 |
| Nguyen, J | 1 |
| Lara, M | 1 |
| Ng, F | 1 |
| Ngo, M | 1 |
| Pham, JM | 1 |
| Yi, Q | 1 |
| Stajich, JM | 1 |
| McDonald, K | 1 |
| Hauser, MA | 1 |
| Wollmann, RL | 1 |
| Evoli, A | 1 |
| Alboini, PE | 1 |
| Damato, V | 1 |
| Iorio, R | 1 |
| Argov, Z | 1 |
| Sha, SJ | 1 |
| Layzer, RB | 1 |
| Lundh, H | 3 |
| Nilsson, O | 3 |
| Rosén, I | 3 |
| Li, L | 1 |
| Zhang, YP | 2 |
| Sanders, DB | 3 |
| Howard, JF | 1 |
| Massey, JM | 2 |
| Vílchez, JJ | 1 |
| Casanova, B | 1 |
| Monte, E | 1 |
| Anlar, B | 1 |
| Varli, K | 1 |
| Ozdirim, E | 1 |
| Ertan, M | 1 |
| Sieb, JP | 1 |
| Sanders, LL | 1 |
| Edwards, LJ | 1 |
| Zheng, W | 1 |
5 reviews available for amifampridine and Myasthenia Gravis
| Article | Year |
|---|---|
3,4-diaminopyridine treatment for Lambert-Eaton myasthenic syndrome in adults: a meta-analysis of randomized controlled trials.
Topics: 4-Aminopyridine; Adult; Amifampridine; Humans; Lambert-Eaton Myasthenic Syndrome; Myasthenia Gravis; | 2021 |
Neuromuscular junction disorders beyond myasthenia gravis.
Topics: Amifampridine; Antibodies; Humans; Lambert-Eaton Myasthenic Syndrome; Myasthenia Gravis | 2021 |
Management of myasthenic conditions: nonimmune issues.
Topics: 4-Aminopyridine; Amifampridine; Cholinesterase Inhibitors; Electrodiagnosis; Humans; Myasthenia Grav | 2009 |
[Diagnosis and therapy of congenital myasthenia syndrome].
Topics: 4-Aminopyridine; Adult; Amifampridine; Central Nervous System Stimulants; Child; Cholinesterase Inhi | 1999 |
[Research progress on a new potassium channel-blocking agent--4-aminopyridine].
Topics: 4-Aminopyridine; Amifampridine; Aminopyridines; Animals; Humans; Ion Channels; Myasthenia Gravis; Po | 1986 |
3 trials available for amifampridine and Myasthenia Gravis
| Article | Year |
|---|---|
3,4-Diaminopyridine in Lambert-Eaton myasthenic syndrome and myasthenia gravis.
Topics: 4-Aminopyridine; Amifampridine; Double-Blind Method; Humans; Lambert-Eaton Myasthenic Syndrome; Myas | 1993 |
3,4-diaminopyridine in childhood myasthenia: double-blind, placebo-controlled trial.
Topics: 4-Aminopyridine; Adolescent; Adult; Amifampridine; Child; Child, Preschool; Cross-Over Studies; Doub | 1996 |
A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome.
Topics: 4-Aminopyridine; Action Potentials; Adult; Amifampridine; Double-Blind Method; Female; Humans; Male; | 2000 |
10 other studies available for amifampridine and Myasthenia Gravis
| Article | Year |
|---|---|
3,4-Diaminopyridine for the treatment of myasthenia gravis with electrophysiological patterns of Lambert-Eaton myasthenic syndrome.
Topics: 4-Aminopyridine; Adult; Aged; Amifampridine; Cholinesterase Inhibitors; Female; Humans; Lambert-Eato | 2018 |
Exome sequencing detection of two untranslated GFPT1 mutations in a family with limb-girdle myasthenia.
Topics: 4-Aminopyridine; Aged; Amifampridine; Base Sequence; DNA Mutational Analysis; Electromyography; Exom | 2014 |
3,4-Diaminopyridine may improve myasthenia gravis with MuSK antibodies.
Topics: 4-Aminopyridine; Amifampridine; Autoantibodies; Female; Humans; Middle Aged; Myasthenia Gravis; Rece | 2016 |
Myasthenia gravis and Lambert-Eaton myasthenic syndrome in the same patient.
Topics: 4-Aminopyridine; Adolescent; Amifampridine; Cholinesterase Inhibitors; Electrodiagnosis; Female; Hum | 2007 |
Novel drug of choice in Eaton-Lambert syndrome.
Topics: 4-Aminopyridine; Aged; Amifampridine; Aminopyridines; Female; Humans; Middle Aged; Myasthenia Gravis | 1983 |
Treatment of Lambert-Eaton syndrome: 3,4-diaminopyridine and pyridostigmine.
Topics: 4-Aminopyridine; Aged; Amifampridine; Aminopyridines; Autoimmune Diseases; Female; Humans; Middle Ag | 1984 |
[Therapy of experimental autoimmune myasthenia gravis in rabbits with 4-aminopyridine and 3,4-diaminopyridine].
Topics: 4-Aminopyridine; Action Potentials; Amifampridine; Animals; Female; Male; Myasthenia Gravis; Rabbits | 1994 |
[3,4-diaminopyridine in the treatment of myasthenic syndromes. Practical aspects].
Topics: 4-Aminopyridine; Amifampridine; Humans; Lambert-Eaton Myasthenic Syndrome; Myasthenia Gravis; Potass | 1996 |
3,4-Diaminopyridine (DAP) in the treatment of Lambert-Eaton myasthenic syndrome (LEMS).
Topics: 4-Aminopyridine; Administration, Oral; Amifampridine; Animals; Follow-Up Studies; Humans; Lambert-Ea | 1998 |
Improvement in neuromuscular transmission in myasthenia gravis by 3,4-diaminopyridine.
Topics: 4-Aminopyridine; Aged; Amifampridine; Aminopyridines; Dose-Response Relationship, Drug; Drug Adminis | 1985 |